Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.69 CAD | +0.27% | -6.82% | -31.28% |
Apr. 08 | Top Premarket Decliners | MT |
Apr. 08 | Eupraxia Pharmaceuticals Inc.(NasdaqCM:EPRX) added to NASDAQ Composite Index | CI |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 131M 95.4M |
---|---|---|---|---|---|
Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 29 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.3% |
1 day | +0.27% | ||
1 week | -6.82% | ||
1 month | -13.18% | ||
3 months | -36.92% | ||
6 months | -26.93% | ||
Current year | -31.28% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | - | 12-07-22 | |
Bruce G. Cousins
DFI | Director of Finance/CFO | 63 | 21-05-02 |
Amanda Malone
CTO | Chief Tech/Sci/R&D Officer | - | 12-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Paul Geyer
BRD | Director/Board Member | 61 | 13-01-13 |
John Montalbano
FOU | Founder | 59 | 11-12-31 |
Richard Glickman
BRD | Director/Board Member | 65 | 21-03-08 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-30 | 3.69 | +0.27% | 15,250 |
24-04-29 | 3.68 | -1.34% | 22,422 |
24-04-26 | 3.73 | -4.36% | 15,050 |
24-04-25 | 3.9 | -0.76% | 6,000 |
24-04-24 | 3.93 | -0.76% | 28,910 |
Delayed Quote Toronto S.E., April 30, 2024 at 03:59 pm EDT
More quotesQuarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-31.28% | 96.03M | |
+0.17% | 42.86B | |
+10.92% | 42.74B | |
+44.30% | 41.36B | |
-6.20% | 27.68B | |
+5.23% | 25.15B | |
-24.79% | 18.63B | |
+26.69% | 12.37B | |
-3.13% | 11.92B | |
+6.57% | 11.21B |
- Stock Market
- Equities
- EPRX Stock